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Abstract A selective PKC inhibitor, UCN-01, was shown to 
exhibit anti-tumor activity in vitro and in vivo. We investigated 
UCN-01 with respect to isozyme-spccific PKC inhibition using 
purified recombinant or rabbit brain PKC isozymes, cPKCa, /3 
and y, nPKC~, E and ~/, and aPKC~. Of the PKC isozymes 
examined, cPKCa was inhibited by UCN-01 most effectively 
(K~ = 0.44 nM), suggesting cPKCc~ is the prime candidate for the 
physiological target of UCN-01. The K~ values of UCN-01 esti- 
mated from Dixon plots for cPKC isozymes are approximately 
1 nM, whereas the K i values for nPKC isozymes are about 20 nM. 
Moreover, the Ki value for aPKC~ is 3.8 btM. Thus, UCN-01 
discriminates between PKC subfamilies. In addition, the inhib- 
itory effects of staurosporine, H7, and calphostin C on aPKC~ 
were examined and compared with those for cPKCw. 
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I. Introduction 
Staurosporine and 7-hydroxy-staurosporine, UCN-01, were 
isolated from actinomyces and have been reported as potent 
protein kinase inhibitors [1,2]. Both inhibitors how variable 
cellular effects, inhibition of proliferation of several tumor cell 
lines, and arrest of the cell cycle [3-6]. UCN-01, however, exhib- 
its in vivo anti-tumor effects against human tumor xenografts 
and murine tumors, while staurosporine has little activity 
against any tumor models [3]. UCN-01 shows selectivity for 
protein kinase C (PKC) inhibition in vitro (ICs0:4.1 nM for 
PKC, 42 nM for protein kinase A, 45 nM for p60 ..... protein 
tyrosine kinase), differing from staurosporine which is a non- 
selective protein kinase inhibitor and inhibits PKC with an 1C50 
of 2.7 nM [1]. Therefore, the anti-tumor activity of UCN-01 
may be due to its selectivity for PKC. 
At present, he mammalian PKC family consists of 11 differ- 
ent polypeptides divided into three subfamilies, conventional 
PKC (cPKC), novel PKC (nPKC), and atypical PKC (aPKC), 
based on their biochemical properties and structure [7,8]. We 
have previously demonstrated that purified nPKC~ and e as 
well as cPKC are inhibited by staurosporine and UCN-01 (ICso 
of staurosporine and UCN-01:0.78 and 1.1 nM for cPKC, 2.0 
and 8.0 nM for nPKCS, 0.61 and 5.5 nM for nPKCe, respec- 
*Corresponding author. 
Abbrev&tions: PKC, protein kinase C; cPKC, conventional PKC; 
nPKC, novel PKC; aPKC, atypical PKC. 
tively) [9]. However, the sensitivity of UCN-01 for other PKC 
isozymes remains to be shown. 
For this report we determined the K~ values of UCN-01 for 
purified PKC isozymes, cPKC~, fl and 7, nPKC~, e and r/, and 
aPKC( from Dixon Plots. In addition, we examined the sensi- 
tivity of aPKC( to the so-called PKC inhibitors, staurosporine, 
H7 [10], and calphostin C [1], because there are few studies on 
the sensitivity of aPKC( to protein kinase inhibitors. 
2. Materials and methods 
2.1. Preparation of PKC isozymes 
cPKCc~, nPKCS, E and r/, and aPKC¢ ~ were xpressed in recombinant 
baculovirus-infected insect cells and purified by sequential chromatog- 
raphy according to reported methods [11,12]. The purification of rabbit 
brain cPKCfl and y has been described previously [13]. Each purified 
PKC samples exhibits a specific activity as follows: cPKCc~, 2,500; 
cPKCfl, 1,600; cPKCy, 1,100; nPKCS, 1,200; nPKCE, 210; nPKCt/, 
100; aPKC~', 240 U/mg protein (1 U = 1 nmol phosphate incorporation 
per minute). 
2.2. PKC assay 
The PKC assay was performed as previously described [14]. Four 
synthetic oligopeptides used as substrates were MBP~4 [14], 
pepMARCKS [11], e-peptide [14], and a-peptide (a cPKC~-pseudosub- 
strate-derived substrate peptide, STASQDVANRFARKGSLRQK- 
NV). Each PKC isozyme in a 50/21 assay mixture (20 mM Tris-HCl, 
pH 7.5, 5 mM Mg(OAc)2, 0.1 mM CaC12, 25/2g/ml phosphatidylserine 
(Avanti Polar Lipid Inc.), 10 ng/ml 12-O-tetradecanoylphorbol-13-ace- 
tate (Sigma), 20/2M ATP, 0.5/2Ci [y-32P]ATP (DuPont-New England 
Nuclear), 0.01% leupeptin and 10-50/2g/ml substrate) was incubated 
for 10 min at 30°C in the presence orabsence of various concentrations 
of PKC inhibitors. UCN-01, staurosporine, and calphostin C were 
isolated from actinomyces or fungi as previously described [1,9]. H7 was 
obtained from Seikagaku Kogyo Co. 
3. Results 
In order to determine the physiological target of UCN-01, 
a compound that shows anti-tumor activity, we investigated 
UCN-01 with respect o isozyme-specific PKC inhibition. The 
Ki values estimated from Dixon plots for purified PKC 
isozymes are summarized inTable 1. The synthetic oligopeptide 
MBP4_14 was used as a substrate because it is a good substrate 
for cPKC and nPKC isozymes. However, MBP 4 14 is a poor 
substrate for aPKC( (data not shown). Thus, a-peptide was 
used as a substrate for aPKC(. The K~ values for the cPKC 
isozymes were in the nanomolar range, consistent with the K, 
value of staurosporine for cPKC0~ (K~ = 0.77 nM) [9]. On the 
other hand, the Ki values for the nPKC isozymes were about 
20 nM, 12- to 56-fold higher than for cPKCs. Furthermore, the 
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K~ value for aPKC( was estimated as 3.8 pM, 2,000- to 10,000- 
and 200-fold higher than for cPKCs and nPKCs, respectively. 
These results indicate that UCN-01 is highly specific for cPKC 
isozymes and especially for cPKC~, and that UCN-01 discrim- 
inates between PKC subfamilies. 
Next we examined the sensitivity of aPKC~" to typical PKC 
inhibitors, staurosporine, H7, and calphostin C, and compared 
the results with those of cPKC~ (Table 2 and Fig. 1). Two 
synthetic oligopeptides, e-peptide and pepMARCKS, were 
used as phosphate acceptors in the PKC assay, aPKC~" turned 
out to be less sensitive to all three inhibitors than cPKC~. The 
calculated ICs0 values of aPKC( for staurosporine were 220 
nM and 450 nM using e-peptide and pepMARCKS, respec- 
tively, 150- and >4,500-fold higher than for cPKC~. On the 
other hand, our previous results indicated that staurosporine 
has almost he same sensitivity for cPKC and nPKC isozymes 
[9]. It has been demonstrated that staurosporine and UCN-01 
interact with the catalytic domain of PKC to inhibit its kinase 
activity [1,2]. H7 also interacts with the catalytic domain of 
PKC and competes with ATP for binding to the enzyme [10]. 
The ICs0 values of H7 for aPKC~" determined using the two 
substrates were 4- and 15-fold higher than those for cPKC~. 
Calphostin C interacts with the regulatory domain of PKC 
which shows significant differences among PKC subfamilies [1]. 
Calphostin C inhibits nPKC5 and e with almost he same IC~0 
as that for cPKC (data not shown), while it inhibits aPKC( with 
ICs0 values of 1 or 6.5/.tM, showing 5- or 30-fold higher sensi- 
tivity for cPKCc~ than aPKC(. 
4. Discussion 
To determine the K~ values of UCN-01 for PKC isozymes, 
first we used MBP 4 ~4 as a substrate. However, MBP 4 14 is a 
poor substrate for aPKC~'. Since the ICs0 values for aPKC( 
examined using four peptide substrates, MBP4 t4, 
pepMARCKS, c~-peptide, and e-peptide, showed almost the 
same (approximately 1 10pM), we determined the K~ value t2w 
aPKC( using ~-peptide which is a good substrate for aPKC(. 
UCN-01 turns out to be an inhibitor that discriminates PKC 
subfamilies. The calculated K~ values of UCN-01 for cPKCs, 
nPKCs, and aPKC~" are approximately 1 nM, 20 nM, and 3.8 
/~M, respectively (Table 1). Among cPKC isozymes, cPKCc~, 
which is expressed ubiquitously ina variety of cells and tissues, 
is inhibited by UCN-01 most effectively, suggesting that 
cPKC~ is a potential candidate for the physiological target of 
UCN-01. The ICs0 values for growth inhibition of tumor cell 
lines by UCN-01, however, are 20 300 nM [3,4], and 0.15 1.56 
/,tM UCN-01 is required to arrest the cell cycle of tumor cell 
Table 1 
K, values of UCN-01 for PKC isozymes 
PKC isozyme K~ (nM) 
cPKC c~ 0.44 
1.70 
y 0.94 
nPKC! 19.5 
e 24.6 
r/ 20.8 
aPKC ( 3800 
The values are the means of three or four separate experiments 
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Fig. 1. Inhibition of aPKC~" (e) and cPKCc~ (A) by staurosporine. 
Enzymatic activity was determined using two synthetic oligopeptides. 
Data are the means of two determinations from two or three separate 
experiments. 
lines [4,6]. Therefore, nPKC isozymes as well as cPKC isozymes 
may play a role in the anti-tumor action of UCN-01 in vivo and 
in vitro. There is also the possibility that another kinase is the 
target for the anti-tumor action of UCN-01. 
The inhibition of aPKC( by staurosporine is less efficient 
than that of cPKC~, consistent with the previous results using 
recombinant aPKC( [15,16]. The ICs0 value of staurosporine 
determined using aPKC~" partially purified from murine pider- 
mis was lower (16 nM) [17], although this aPKC~" preparation 
was crude and its kinase activity significantly weak. 
Several staurosporine-related inhibitors, K252a [14], K252b 
[18], Ro 32 0432 [19], G6 6976, and G6 6850 [20], have been 
reported to discriminate PKC subfamilies in the inhibition of 
their kinase activity. For these inhibitors, interference in the 
binding of ATP to the kinase has been shown to be the mech- 
anism of inhibition [19-21]. Nonetheless, inhibition of PKC by 
staurosporine is not influenced by excess ATP [1] and the mo- 
lecular basis for inhibition remains unknown. The ICs0 values 
of H7, an ATP competitor, and calphostin C, an inhibitor 
interacting with the regulatory domain of PKC, for cPKC~ and 
aPKC~" change somewhat depending on the substrate used. On 
the other hand, the difference in the ICs0 values of stauro- 
sporine for cPKCc~ was drastic depending on which of the two 
substrates was used (Table 2 and Fig. 1). In addition, stauro- 
sporine shows almost he same sensitivity for cPKC and nPKC 
isozymes when the synthetic peptides MBP 4 14 [9] and peptide-y 
[19] are used as substrates, although there is a 100-fold selectiv- 
ity for cPKCc~ over nPKC~ when protamine sulfate is used [15]. 
These results uggest that staurosporine interacts with the sub- 
strate binding domain of PKC. Taken together, the finding that 
the ATP-binding sites of PKC isozymes are conserved and that 
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Table 2 
Comparison of the inhibition of aPKC( and cPKC0~ by staurosporine, H7, and calphostin C
261 
Staurosporine lC5~ (nM) H7 IC5~ ~M) Calphostin C IC50 (nM) 
e-peptide pepMARCKS e-peptide pepMARCKS e-peptide pepMARCKS 
cPKC~ 1.5 < 0.1 24 20 200 200 
aPKC( 220 450 90 300 1000 6500 
c~/g" 1/150 < 1/4500 1/4 1/15 1/5 1/33 
The values are averages of two or three separate xperiments 
H7, an ATP competitor, shows a similar sensitivity for PKC 
isozymes (Table 2) [14], staurosporine and its related com- 
pounds including UCN-01 may recognize a subtle differences 
not only in the ATP-binding domain but also in the substrate- 
binding site of PKC isozymes. These drugs may be useful tools 
with which to analyze structural differences in the catalytic 
domain of PKC isozymes. Further investigations using intact 
proteins and physiological substrates are needed to determine 
the sensitivity of PKC isozymes for inhibitors, because the ICs0 
value of staurosporine for cPKC~ depends on the substrate 
used. 
Calphostin C has been reported to interact with the C1 do- 
main of PKC [7], because inhibition by calphostin C is not 
influenced by the concentration of phosphatidylserine or Ca 2+ 
and because it inhibits the binding of phorbol esters to PKC 
[22]. Moreover, calphostin C dose not inhibit the kinase activity 
of catalytic fragment of PKC [1,22]. Since aPKC(  has a signif- 
icantly different regulatory domain from cPKC and nPKC 
isozymes, we expected that calphostin C did not inhibit aPKC(.  
However, calphostin C inhibits not only cPKC and nPKC but 
also aPKC(  with only a 5- to 30-fold higher ICs0, suggesting 
that calphostin C recognizes the regulatory domain of aPKC(  
as well as those of cPKCs and nPKCs, cPKC and nPKC 
isozymes have the C1 domains with repeated cysteine-rich se- 
quences and are dependent on phorbol esters, while aPKC(  
contains only one cysteine-rich sequence and its kinase activity 
is independent of phorbol esters or diacylglycerols [7,8]. Re- 
combinant aPKC(  produced by baculovirus-insect cell systems 
has been reported to exhibit constitutive kinase activity which 
is independent of phosphatidylserine and diacylglycerol [ 15,16], 
although aPKC(  purified from bovine kidney showed kinase 
activity dependent on phosphatidylserine [23]. Our recombi- 
nant aPKC(  also showed phosphatidylserine d pendency and 
this dependency disappeared by limited fragmentation of 
aPKC(  with calpain treatment, which produced a free catalytic 
fragment of aPKC(  (Ueda, Y. et al., manuscript in prepara- 
tion). In addition, it has been reported that phosphatidylinosi- 
tol-3,4,5-P~ and arachidonic acid activate aPKC(  [16,23,24]. 
The fact that the regulatory domain of aPKC(  contains a 
psuedosubstrate sequence also suggests the regulation of 
aPKC(  by binding of various lipid activators to the regulatory 
domain in a similar way as cPKCs and nPKCs. From these 
results, inhibition of aPKC(  by calphostin C is most likely due 
to the interaction of the inhibitor and the regulatory domain 
of aPKC~" which contain one cysteine rich domain. 
In this report, we determined the K~ values of UCN-01 for 
PKC isozymes and demonstrated that UCN-01 inhibits cPKCc~ 
most effectively and that it discriminates PKC subfamilies. Fur- 
thermore, we found that aPKC(  shows less sensitivity for stau- 
rosporine than cPKC~, while H7 and calphostin C inhibit 
aPKC(wi th  a sensitivity similar to that for cPKCs and nPKCs. 
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